NovaBridge and Visara Post Strong VIS-101 Phase 2a Wet AMD Data, Plot Path to Late-Stage Trials

NovaBridge Biosciences ( (NBP) ) just unveiled an update.

On March 9, 2026, NovaBridge Biosciences and its subsidiary Visara reported positive topline Phase 2a results for VIS-101 in wet age-related macular degeneration, with both 3 mg and 6 mg cohorts showing mean best-corrected visual acuity gains of more than 10 ETDRS letters and median central subfield thickness reductions of 100–150 micrometers. The randomized study in 38 patients in China also showed that roughly two-thirds of patients were retreatment-free at four months and about half at six months after three loading doses, alongside a favorable safety profile with no dose-limiting toxicity and low rates of treatment-emergent adverse events.

Clinical experts cited the data as among the most encouraging for a dual VEGF-A/ANG-2 inhibitor at this stage, highlighting durability as a key unmet need and suggesting that, if future Phase 3 data confirm these findings, VIS-101 could see broad adoption in retinal vascular disease. NovaBridge’s management characterized the results as an important inflection point that de-risks VIS-101’s development and underscores the value-creation potential of its global biotech platform, with a dose-determining Phase 2b study planned for the second half of 2026 and a global Phase 3 program targeted to start in 2027.

The most recent analyst rating on (NBP) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page.

Spark’s Take on NBP Stock

According to Spark, TipRanks’ AI Analyst, NBP is a Neutral.

The score is primarily held back by deteriorated financial performance (no 2024 revenue, persistent losses, and ongoing cash burn) despite low leverage. Technicals are mildly bearish with price below key moving averages and a slightly negative MACD, while valuation is largely neutral because negative earnings make the P/E less informative and no dividend support is shown.

To see Spark’s full report on NBP stock, click here.

More about NovaBridge Biosciences

NovaBridge Biosciences is a Nasdaq-listed global biotechnology platform company focused on accelerating access to innovative medicines through a “hub-and-spoke” model, partnering with specialized teams to advance differentiated programs. Its majority-owned subsidiary Visara, Inc., is a clinical-stage biopharmaceutical company developing best-in-class ophthalmic therapeutics, including VIS-101 for retinal vascular diseases such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

Visara controls global rights to VIS-101 outside Greater China and certain Asian markets, positioning NovaBridge to participate in large, growing markets for retinal disease therapies affecting tens of millions of patients worldwide. The companies are targeting dual VEGF-A/ANG-2 inhibition as an emerging standard of care pathway, aiming to compete on durability and safety against current treatments, which impose a high injection burden on patients and healthcare systems.

Average Trading Volume: 714,518

Technical Sentiment Signal: Hold

Current Market Cap: $403.5M

Find detailed analytics on NBP stock on TipRanks’ Stock Analysis page.